文献速递血管炎

托珠单抗治疗巨细胞动脉炎的复发情况:临床实践中407例患者的回顾性多中心研究

Relapses in giant cell arteritis treated with tocilizumab. Retrospective multicenter study of 407 patients in clinical practice.
PubMed 文献 · Semin Arthritis Rheum · 2025-01-29

这项回顾性多中心观察性研究纳入2016至2021年间接受托珠单抗治疗的407例巨细胞动脉炎患者,平均随访25.3±21.7个月,63/407例(15.5%)出现复发,均为非严重复发;多变量分析显示复发与托珠单抗开始晚于6周、优化、静脉给药及托珠单抗前既往治疗相关。

要点

  • 407例接受托珠单抗治疗的巨细胞动脉炎患者中,63例(15.5%)复发,均为非严重复发。
  • 首次复发中位时间为12[6-24]个月,最常见表现为风湿性多肌痛(47.6%)和头痛(12.7%)。
  • 复发相关因素包括托珠单抗开始晚于6周、优化、静脉给药及托珠单抗前既往治疗。

核心结论

  • 该系列中15%的巨细胞动脉炎患者出现复发,均为非严重复发;复发与托珠单抗治疗方案(静脉给药、优化、延迟开始及托珠单抗前既往治疗)相关。

研究设计与样本

  • 回顾性多中心观察性研究,纳入2016至2021年间接受托珠单抗治疗的407例巨细胞动脉炎患者(295例女性;平均年龄73.6±8.9岁)。
  • 收集托珠单抗启动时的人口学、临床、实验室、颞动脉活检、影像学、糖皮质激素剂量、既往治疗及托珠单抗治疗方案变量。
  • 进行有无复发患者的双变量比较及与复发相关因素的多变量logistic回归分析。

主要发现

  • 平均随访25.3±21.7个月后,63/407例(15.5%)患者出现复发。
  • 托珠单抗启动时,有无复发两组在人口学、临床、实验室特征或糖皮质激素剂量方面无差异。
  • 首次复发中位时间为12[6-24]个月;最常见复发表现为风湿性多肌痛(47.6%)和头痛(12.7%)。
  • 多变量logistic回归中,与巨细胞动脉炎复发相关的变量包括托珠单抗开始晚于6周(OR 3.446[1.196-9.931])、优化(OR 2.803[1.507-5.215])、静脉给予托珠单抗(OR 2.327[1.244-4.353])及托珠单抗前既往治疗(OR 5.062[2.402-10.665])。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Tocilizumab (TCZ) is the only biologic approved in Giant Cell Arteritis (GCA). In clinical trials around a quarter of patients relapse during TCZ treatment. We assess the frequency, features and factors associated with relapses in a wide series of GCA patients in a real-world setting. METHODS: National multicenter observational study of GCA patients treated with TCZ between 2016 and 2021. The variables collected at TCZ initiation were demographic, clinical, laboratory, temporal artery biopsy, and imaging findings, corticosteroids dose, previous therapies and TCZ therapeutic schedule. We perform a comparative study between patients with/ without relapses (bivariate analysis) and a study of factors associated with relapse (multivariate logistic). RESULTS: We study 407 patients (295 women; mean age 73.6 ± 8.9 years). After a mean follow-up of 25.3 ± 21.7 months, relapses were observed in 63 of 407 (15.5 %) patients. At TCZ initiation, no differences were observed between both groups (with/without relapses) in demographic, clinical and laboratory features or corticosteroid dose. The median time to the first relapse was 12 [6-24] months being the most frequent manifestations polymyalgia rheumatica (47.6 %), and headache (12.7 %). In multivariate logistic regression analysis, the set of variables associated with GCA relapses were TCZ initiation later than 6 weeks (OR 3.446 [1.196- 9.931]), optimization (OR 2.803 [1.507-5.215]) and administration of IV TCZ (OR 2.327 [1.244-4.353]) and previous therapies to TCZ (OR 5.062[2.402-10.665]). CONCLUSION: In this series, GCA relapses were observed in 15 % of patients, all of them non-severe. Relapses were associated with TCZ therapeutic schedule, such as IV administration, optimization, delayed initiation and previous therapies to TCZ.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Martín-Gutiérrez A, Loricera J, Aldasoro V, et al. Relapses in giant cell arteritis treated with tocilizumab. Retrospective multicenter study of 407 patients in clinical practice. Semin Arthritis Rheum. 2025. PMID: 39899915. doi:10.1016/j.semarthrit.2025.152640

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。